Addressing the challenges of developing BioSimilars




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Addressing the challenges of developing BioSimilars
Released on: June 05, 2015. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Talking to PharmaVentures'CEO, Dr Fintan Walton, Dr Wolfgang Baiker, Corporate Board Divisions Operations and Biopharmaceuticals at Boehringer Ingelheim explains that BioSimilars will make a significant contribution to the future growth and sales of the organisation.
  • Summary
  • Transcript
  • Participants
  • Company
Talking to PharmaVentures'CEO, Dr Fintan Walton, Dr Wolfgang Baiker, Corporate Board Divisions Operations and Biopharmaceuticals at Boehringer Ingelheim explains that BioSimilars will make a significant contribution to the future growth and sales of the organisation.
Talking to PharmaVentures'CEO, Dr Fintan Walton, Dr Wolfgang Baiker, Corporate Board Divisions Operations and Biopharmaceuticals at Boehringer Ingelheim explains that BioSimilars will make a significant contribution to the future growth and sales of the organisation.
Boehringer Ingelheim
Boehringer Ingelheim
Boehringer Ingelheim GmbH is a pharmaceutical company which concentrates on the development of human pharmaceuticals, biopharmaceuticals, chemicals, and animal health products. The Human Pharmaceuticals sector is the company's largest division, accounting for about 96% of sales. This includes prescription medicines and consumer healthcare products.